← All trials
NCT04731298
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 15, 2021
- Primary completion
- Jun 30, 2022
- Completion date
- Dec 31, 2024
- First posted
- Jan 29, 2021
- Last posted
- May 4, 2021
- Enrollment
- 250
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Swedish Orphan BiovitrumLead sponsor
- Peter MacCallum Cancer CentreOverall official - principal investigator
- Pharmaceutical Research Associates, Inc. (PRA)Collaborator
- CromsourceCollaborator
- St. Justine's HospitalOverall official - principal investigator
- BioMérieuxCollaborator
- Q2 solutionsCollaborator
- Cytel Inc.Collaborator
- GxP ConsultingCollaborator
- Hebrew UniversityOverall official - principal investigator
- Sydney Children's Hospitals NetworkOverall official - principal investigator
- Rambam Health Care CampusOverall official - principal investigator
- ProteinsimpleCollaborator
- ABF Pharmaceutical Services GmbHCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.